| Correspondence on “PICaSSO Histologic Remission Index (PHRI) in ulcerative colitis: development of a novel simplified histological score for monitoring mucosal healing and … ECL Wong, PS Dulai, N Narula Gut 72 (4), 805-807, 2023 | 2 | 2023 |
| A serum biomarker panel can accurately identify mucosal ulcers in patients with Crohn’s disease AK Holmer, BS Boland, S Singh, J Neill, H Le, A Miralles, AE Collins, ... Inflammatory bowel diseases 29 (4), 555-562, 2023 | 5 | 2023 |
| Effectiveness of reinduction and/or dose escalation of ustekinumab in Crohn’s disease: a systematic review and meta-analysis J Meserve, C Ma, PS Dulai, V Jairath, S Singh Clinical Gastroenterology and Hepatology 20 (12), 2728-2740. e1, 2022 | 43 | 2022 |
| Effect of obesity on risk of hospitalization, surgery, and serious infection in biologic-treated patients with inflammatory bowel diseases: a CA-IBD cohort study P Gu, J Luo, J Kim, P Paul, B Limketkai, JS Sauk, S Park, N Parekh, ... Official journal of the American College of Gastroenterology| ACG 117 (10 …, 2022 | 18 | 2022 |
| Decision support tool identifies ulcerative colitis patients most likely to achieve remission with vedolizumab vs adalimumab PS Dulai, ECL Wong, W Reinisch, JF Colombel, JK Marshall, N Narula Inflammatory bowel diseases 28 (10), 1555-1564, 2022 | 9 | 2022 |
| Recommendations for standardizing clinical trial design and endoscopic assessment in postoperative Crohn’s disease J Hanzel, V Jairath, P De Cruz, L Guizzetti, LM Shackelton, P Bossuyt, ... Inflammatory bowel diseases 28 (9), 1321-1331, 2022 | 8 | 2022 |
| Recommendations on the appropriate management of steroids and discharge planning during and after hospital admission for moderate-severe ulcerative colitis: results of a RAND … PS Dulai, V Rai, LE Raffals, D Lukin, D Hudesman, GS Kochhar, ... Official journal of the American College of Gastroenterology| ACG 117 (8 …, 2022 | 4 | 2022 |
| Real‐world multicentre observational study including population pharmacokinetic modelling to evaluate the exposure–response relationship of vedolizumab in inflammatory bowel … N Vande Casteele, WJ Sandborn, BG Feagan, S Vermeire, PS Dulai, ... Alimentary Pharmacology & Therapeutics 56 (3), 463-476, 2022 | 19 | 2022 |
| Mental health symptom reduction using digital therapeutics care informed by genomic SNPs and gut microbiome signatures I Pedroso, SV Kumbhare, B Joshi, SK Saravanan, DS Mongad, ... Journal of Personalized Medicine 12 (8), 1237, 2022 | 6 | 2022 |
| Comparative effectiveness of biologics for endoscopic healing of the ileum and colon in Crohn's disease N Narula, ECL Wong, PS Dulai, JK Marshall, V Jairath, W Reinisch Official journal of the American College of Gastroenterology| ACG 117 (7 …, 2022 | 39 | 2022 |
| Comparative efficacy for infliximab vs vedolizumab in biologic naive ulcerative colitis N Narula, ECL Wong, JK Marshall, JF Colombel, PS Dulai, W Reinisch Clinical Gastroenterology and Hepatology 20 (7), 1588-1597. e3, 2022 | 19 | 2022 |
| Comparative efficacy and rapidity of action for infliximab vs ustekinumab in biologic naïve Crohn’s disease N Narula, ECL Wong, PS Dulai, NK Sengupta, JK Marshall, JF Colombel, ... Clinical Gastroenterology and Hepatology 20 (7), 1579-1587. e2, 2022 | 33 | 2022 |
| Dual Advanced Therapies and Novel Pharmacotherapies for Moderately to Severely Active Crohn's Disease CS Tse, PS Dulai Gastroenterology Clinics 51 (2), 283-298, 2022 | | 2022 |
| Predicting endoscopic remission in Crohn’s disease by the modified multiplier SES-CD (MM-SES-CD) N Narula, ECL Wong, JF Colombel, WJ Sandborn, JK Marshall, ... Gut 71 (6), 1078-1087, 2022 | 25 | 2022 |
| Early change in epithelial neutrophilic infiltrate predicts long-term response to biologics in ulcerative colitis N Narula, ECL Wong, JF Colombel, R Riddell, JK Marshall, W Reinisch, ... Clinical Gastroenterology and Hepatology 20 (5), 1095-1104. e9, 2022 | 26 | 2022 |
| Resolution of dominant patient‐reported outcome at end of induction predicts clinical and endoscopic remission in Crohn’s disease ECL Wong, PS Dulai, JK Marshall, V Jairath, W Reinisch, N Narula Alimentary Pharmacology & Therapeutics 55 (9), 1151-1159, 2022 | 4 | 2022 |
| Clinical decision support tool for infliximab in Crohn’s disease PS Dulai, ECL Wong, W Reinisch, N Narula Clinical Gastroenterology and Hepatology 20 (5), e1192-e1195, 2022 | 2 | 2022 |
| Ulcerative colitis: clinical manifestations and management S Singh, PS Dulai Yamada's Textbook of Gastroenterology, 1248-1293, 2022 | 4 | 2022 |
| is it not just PROs, but the most important individual PRO, that really matters in Crohn's disease? Authors' reply. ECL Wong, PS Dulai, JK Marshall, V Jairath, W Reinisch, N Narula Alimentary Pharmacology & Therapeutics 55 (8), 2022 | | 2022 |
| Preserved SARS-CoV-2 vaccine cell-mediated immunogenicity in patients with inflammatory bowel disease on immune-modulating therapies BS Boland, B Goodwin, Z Zhang, N Bloom, Y Kato, J Neill, H Le, T Tysl, ... Clinical and translational gastroenterology 13 (4), e00484, 2022 | 8 | 2022 |
